Approximately two-thirds of patients with Crohn's disease who initially responded to tumor necrosis factor (TNF) inhibitors lost response by the third year of treatment, a population-based ...

Continuing anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy is associated with a lower likelihood of relapse of inflammatory bowel disease (IBD) in pregnant women and fewer ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn's ...

LAS VEGAS -- Children and teens with Crohn's disease who received early tumor necrosis antagonist (anti-TNF) treatment had a lower risk of developing perianal fistulizing complications (PFCs) than ...

Starting anti-TNF treatment at diagnosis is more cost-effective than accelerated step-up care for active Crohn’s disease, saving £1681 per patient over 5 years while improving clinical outcomes by ...

Please provide your email address to receive an email when new articles are posted on . At baseline, 26.6% of children with Crohn’s had a weight disturbance, 27.7% had a height disturbance and 19.7% ...

Anti-TNF-α biosimilars showed a 91% drug survival rate at 12 months, with no significant differences between infliximab, etanercept, and adalimumab. Long-term effectiveness and safety of anti-TNF-α ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn's ...

Alopecia areata is more prevalent in patients with IBD, especially those on anti-TNF therapy, compared with controls. The study found no significant difference in alopecia improvement between those ...

Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s ...